Innovative pharmaceutical interventions in cardiovascular disease: Focusing on the contribution of non-HDL-C/LDL-C-lowering versus HDL-C-raising A systematic review and meta-analysis of relevant preclinical studies and clinical trials

Kuhnast, S.; Fiocco, M.; Hoorn, J.W.A. van der; Princen, H.M.G.; Jukema, J.W. (2015)

Article / Letter to editor

• Cardiovascular disease
• Clinical outcome
• Myocardial infarction
• LDL-cholesterol
• Non-HDL-cholesterol
• HDL-cholesterol
• Atherosclerosis
• Clinical trials
• APOE*3Leiden.CETP mice
• Mouse
• Rabbit
• Hamster
• Niacin
• Fibrates
• Glitazones
• PPAR agonists
• CETP inhibition
• SR-BI inhibitor
• ABCA1 degradation inhibitors
• Reconstituted HDL
• Delipidated HDL
• Apolipoprotein A-I Milano
• Apolipoprotein A-I mimetic
• Apolipoprotein A-I inducer
• LCAT

• All authors: Kuhnast, S.; Fiocco, M.; Hoorn, J.W.A. van der; Princen, H.M.G.; Jukema, J.W.
• Date: 2015-09-15
• Journal: European Journal of Pharmacology
• Volume: 763
• Pages: 48 - 63
• DOI: doi:10.1016/j.ejphar.2015.03.089